The effect of cystatin-C and pro-BNP in determining mortality in elderly patients with sepsis: Sepsisli yaşlı hastalarda mortaliteyi belirlemede sistatin-C ve pro-BNP’nin etkisi

Öykü Aksoy Arslan; Güzin Öztürk; Burak Arslan; Tufan Tükek

doi:10.5455/GMJ-30-45929

Authors

Öykü Aksoy Arslan İzmir Bozyaka Education and Research Hospital, Internal Medicine Clinic, İzmir, Turkey 2Sultanbeyli 9th Family Health Center, İstanbul
Güzin Öztürk Sultanbeyli 9th Family Health Center, İstanbul
Burak Arslan İzmir Bozyaka Education and Research Hospital, Urology Clinic, İzmir
Tufan Tükek Department of Internal Medicine, Faculty of Medicine, İstanbul University, İstanbul

DOI:

https://doi.org/10.5455/GMJ-30-45929

Keywords:

Cystatin-C; glomerular filtration rate, natriuretic peptides, sepsis

Abstract

In this study we examined whether cystatin-C, pro-BNP, procalcitonin and C-reactive protein (CRP) is valuable in predicting multiorgan failure and mortality in elderly (≥ 65) patients with sepsis. A total of 35 patients who were treated for sepsis in hospital were included in the study. Chronic renal failure, hypothyroidism or hyperthyroidism, known history of diabetes and patients with heart failure were excluded from the study. Cystatin-C, pro-BNP, procalcitonin and CRP levels were measured besides the routine biochemical examinations. Patients were divided into two groups according to their in hospital outcome in terms of mortality. There was no statistically significant difference in patients age, CRP, cystatin-C, pro-BNP, procalcitonin, BUN, creatinine, leukocyte count, hemoglobin and platelet count according to the etiology of sepsis. However there was a significant difference in mortality rate between pneumonia and cholangitis groups with the others. Cystatin-C (p=0.031) and pro-BNP (p=0.023) levels were significantly higher in mortality group when both groups were compared. Increase of cystatin-C and pro-BNP levels were detected in elderly patients with sepsis or septic shock. The cystatin-C and pro-BNP levels can be used as an indicator of early mortality in these patients.

Metrics

Metrics Loading ...

References

Saçar S, Hırçın-Cenger D, Asan A, Toprak-Kavas S, Demir M, Turgut H. Geriatrik İnfeksiyonların 50 Olguda Değerlendirilmesi. Pamukkale Tıp Dergisi 2008;1(2):84-6.

Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348(16):1546-54.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29(7):1303-10.

Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138-150.

Vincent JL. Sepsis definitions. Lancet Infect Dis 2002;2(3):135.

Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profilein patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000;181(1):176-80.

Braithwaite S. Prokalcitonin: New insights on regulation and origin. Crit Care Med 2000;28(2):586-8.

Oberhoffer M, Karzai W, Hellmann AM, Bögel D, Fabbinder J, Reinhart K. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factorand interleukin-6 in patients with sepsis. Crit Care Med 1999;27(9):1814-8.

Lynn WA, Cohen J. Adjunctive theraphy for septic shock: A rewiev of experimental approaches. Clin Infect Dis 1995;20(1):143-58.

Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999;230:132-42.

Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. Rev Cardiovasc Med 2003;4(Suppl 4):29-36.

Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, et al. Circulating natriuretic peptit concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodelling. Mayo Clin Proc 2001;76(11):1111-9.

Brguljan PM, Cimerman N. Human cystatin C. Turk J Biochem 2007;32(3):95-103.

Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C-a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998;101(5):875-81.

Helin I, Axenram M, Grubb A. Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol 1998;49(4):221-5.

Girard TD, Opal SM, Ely EW. Insights into severe sepsis in older patients: from epidemiology to evidence-based management. Clin Infect Dis 2005;40(5):719-27.

Opal SO, Girard DT, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Inf Dis 2005;41(7):504-12.

Warfel AH, Zucker-Franklin D, Frangione B, Ghiso J. Constitutive secretion of cystatin C (gamma-trace) by monocytes and macrophages and its downregulation after stimulation. J Exp Med 1987;166(6):1912-7.

Galteau MM, Guyon M, Gueguen R, Siest G. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001;39(9):850-7.

Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, et al. Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol 2008;63(6):798-802.

Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004;66(3):1115-22.

Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB,et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352(20):2049–60.

Ni L, Lü J, Hou LB, Yan JT, Fan Q, Hui R, et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 2007; 38(12): 3287–8.

Bell M, Granath F, Mårtensson J, Löfberg E, Ekbom A, Martling CR. Cystatin C is correlated with mortality in patients with and without acute kidney injury. Nephrol Dial Transplant 2009;24(10):3096-102.

Levy J, Morgan J, Brown E. SDBH koplikasyonları: Kardiovasküler hastalık. In: Uslan I, Editor. Oxford Diyaliz El Kitabı. İstanbul, Nobel Kitapevi, 2002;474-84.

McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptides for identifying left ventricular sistolic dysfunction in primary care. BMJ 1998;317(7157):516-9.

Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006;34(8):2140-4.

Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K, et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005;33(5):1001-7.

Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005;112(4):527-34.

Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V, FINNSEPSIS Study Group. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007;35(5):1277-83.